March 3, 2023 7:47am
Pre-open Indications: 2 Positive and 2 Sell into Strength
The Biostage (OTCQB: BSTG) Chronicles: WHO is really running this company, WHAT is the relationship with … LIU Dong-hai of D Phone and Dixintong Technology Group in China of which Jason Chen, a BSTG board member and a VP Dixintong. WHAT is LIU Dong-hai’s relationship with DST Capital in funding the company, managed and Mrs. bin Zhao (his wife?) and BSTG’s president Hong Yu (a double role?). Questio#2: HOW many times did Shunfu Hu, VP of business development and operations say to me – that Beijing, China based LIU Dong-hai was the ULTIMATE AUTHORITY? Question#3: is BSTG a PONZI scheme with its pump (volume)/promote (share pricing) scheme?
A daily report may say little or a lot and its final judgement may be inconclusive; yet it serves as insurance that all indications are being examined, evaluated and reported.
Subscription is coming, it’s not conscription but, an offer to join our collective of like-minded investors! Join me … in the NO spin zone.
The 8:00 a.m. edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session. My interpretation of the morning’s numbers is written to be informative; it’s built on will happen behind the headlines today, not tomorrow or yesterday …
Dow futures are UP +0.24% or (+80 points), S&P futures are UP +0.31% or (+12 point) and NASDAQ futures are UP +0.27% or (+32 points) early in the pre-open – so far
U.S. stock futures are rising on Friday
Europe markets are climbing,
Asia Pacific markets are also on the rise.
Henry’omics:
We need to understand the macro to comprehend the micro re “our” universe of cell and gene therapy companies …
Indexes flipped to the upside after a fluctuating session.
Last night, the session closed with the Dow closing UP +341.73 points (+1.05%); the S&P closing UP +29.96 points (+0.76%) while the Nasdaq closed UP +83.50 points (+0.73%)
The major averages are on their way to a positive week. The S&P 500 is up 0.28%, on pace to snap a three-week decline, while the Nasdaq has a 0.6% gain. The Dow is also up 0.6% on the week. <CNBC>
Economic Data Docket: The Institute of Supply Management is due to release its Non-Manufacturing Purchasing Managers’ Index (PMI) report
Thursday’s (3/2) … RegMed Investors’ (RMi) closing bell: “the cell and gene therapy sector’s feeling the lack of sentiment.” … https://www.regmedinvestors.com/articles/12852
RegMed Investors (RMi) Research Note: Upcoming Q4 earnings reporting dates … https://www.regmedinvestors.com/articles/12830
RegMed Investors (RMi) Research Note: Q4 and FY22 earnings reporting … “The cell and gene therapy sector fluctuates in revenues, collaboration, regulatory submissions and expenses, but the changes may alarm investors who prefer to see expectation and consensus stability and share pricing growth” … https://www.regmedinvestors.com/articles/12843
Ebb and flow:
Q1/23 –
March – 2 negative close
· February – 1 holiday, 2 vacation, 7 negative and 8 positive closes
· January – 2 holidays, 11 positive and 9 negative closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
Positive indications: dollar ($) and cent ($0.00) value and percentage (%)
· Agenus (AGEN) +$0.03 or +1.55%
· Verve therapeutics (VERV) +$0.84 or +4.17%
Sell into Strength: dollar ($) and cent ($0.00) value and percentage (%)
· BioLife solutions (BLFS) +$0.47 or +2.02%
· uniQure NV (QURE) -$0.60 or -2.78%
The BOTTOM LINE: I try to keep it simple and short!
Investors are STILL dependent on the economics in relation to inflation “if the indexes break down further, (sector upside) leaders will continue to crumble. It's hard to see the major indexes holding up if Treasury yields keep marching higher. Friday's (today’s) ISM services index, and the market reaction to that report, will be important.”
The rush of Q4 and FY22 earnings to release is on … I do NOT believe there aren't a lot of cell/gene therapy companies in position yet – UNTIL earnings (Q4 and FY22) are reported – any breakout is a false hope with the inevitable downside re-occurring.
15 of my 35 covered have reported.
I also hate to be so negative or contrarian but, this is a NO spin zone and truth is its product.
And I can always be WRONG but, mostly EARLY!
Upcoming Q4 earnings reporting will present challenges to share pricing.
· Voyager Therapeutics (VYGR) 3/7 – Tuesday
· Cellectis SA (CLLS) 3/9 - Thursday
· Agenus (AGEN) 3/14 – Tuesday
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
